135| Neuropsychology’s Role in Anti-Amyloid Therapies – A Conversation With Dr. Kevin Duff

Today we give you a discussion with Dr. Kevin Duff about neuropsychologists’ role with respect to lecanemab and other antiamyloid therapies.

About Kevin

Dr. Kevin Duff has specialized in neuropsychology for over 20 years. He obtained his Ph.D. in Clinical Psychology from the State University of New York in Albany. He completed his neuropsychology internship at the Southern Arizona Healthcare System in Tucson, AZ, and his post-doctoral fellowship at the University of Oklahoma Health Sciences Center in Oklahoma City. He joined the Psychiatry Department at the University of Iowa in 2003, where had clinical and research responsibilities working with patients with dementia, Huntington’s disease, and a variety of other neuropsychiatric conditions. In 2009, he joined the University of Utah as Associate Professor of Neurology and neuropsychologist for Alzheimer’s Care, Imaging and Research. In 2022, he moved (hopefully for the last time) to Oregon Health & Science University in Portland, where he is the senior neuropsychologist at the Layton Aging & Alzheimer’s Disease Research Center and Professor in their Department of Neurology.

Dr. Duff’s research has focused primarily on the early identification of cognitive decline in neuropsychiatric illnesses. Across multiple studies, Dr. Duff has used short-term practice effects as a marker of brain plasticity in patients with Mild Cognitive Impairment to examine if short-term changes in cognition can predict the diagnosis and prognosis of dementia, as well as its brain pathology and response to interventions. He has published over 180 peer-reviewed papers in scientific journals and he has lectured nationally and internationally on his areas of expertise. His research on practice effects in Mild Cognitive Impairment has been continually funded by the National Institutes of Health since 2005.